{
  "id": "3b47b3f0-dd90-474b-a108-f5a841e03332",
  "title": "Halozyme plans finance $2.1 takeover of Evotech in cash: report",
  "link": "https://seekingalpha.com/news/4300274-halozyme-plans-finance-21-takeover-of-evotech-in-cash-report?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Sun, 17 Nov 2024 18:28:20 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "hal",
    "jnj",
    "bmy"
  ],
  "byline": "Rob Johnson",
  "length": 300,
  "excerpt": "More on Evotec SE, Halliburton, etc. Halliburton Company (HAL) Q3 2024 Earnings Call Transcript Evotec SE (EVO) Q3 2024 Earnings Call Transcript Evotec SE 2024",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Solskin Halozyme Therapeutics (NYSE:HAL) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (EVO) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley. “We feel confident in being able to fund this as a fully cash deal,” Torley Recommended For You",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e \u003cpicture\u003e \u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w750\" alt=\"Scientist looking into microscope\" data-id=\"1386962536\" data-type=\"getty-image\" width=\"1536px\" height=\"996px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962536/image_1386962536.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e \u003c/picture\u003e \u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003eSolskin\u003c/p\u003e\u003c/figcaption\u003e \u003c/figure\u003e\u003cdiv id=\"more-links\"\u003e  \u003cp\u003eHalozyme Therapeutics (\u003cspan\u003eNYSE:\u003ca href=\"https://seekingalpha.com/symbol/HAL\" title=\"Halliburton Company\"\u003eHAL\u003c/a\u003e\u003c/span\u003e) intends to finance its 2B euro ($2.1B) proposed acquisition of Germany’s Evotec (\u003ca href=\"https://seekingalpha.com/symbol/EVO\" title=\"Evotec SE\"\u003eEVO\u003c/a\u003e) in cash, Bloomberg reported Sunday, quoting Chief Executive Helen Torley.\u003c/p\u003e \n\u003cp\u003e“We feel confident in being able to fund this as a fully cash deal,” Torley \u003c/p\u003e \u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2024-11-17T23:28:20Z",
  "modifiedTime": "2024-11-17T18:36:42-05:00"
}
